PRUXELUTAMIDE
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Suzhou Kintor Pharmaceutical Inc,Small moleculePhase 2Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
230 Active assets in the Metastatic Castrate Resistant Prostate Cancer (mCRPC) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Darolutamide Bayer | Phase 4 | BBB |
Enzalutamide Prostate Cancer Clinical Trials Consortium | Phase 4 | BBB |
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE Ding-Wei Ye | Phase 4 | BBB |
Darolutamide Bayer | Phase 3 | BB |
RADIUM RA-223 Bayer | Phase 4 | BB |
View all 50 →
Same molecule, other indications
PRUXELUTAMIDE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →